NRAS Codon 59 Missense
Back to Biomarkers List
Associated Genetic Biomarkers
NRAS Codon 59 Missense is present in 0.07% of AACR GENIE cases, with acute myeloid leukemia with maturation, cutaneous melanoma, infiltrating renal pelvis and ureter urothelial carcinoma, lung adenocarcinoma, and melanoma having the greatest prevalence .
NRAS Codon 59 Missense serves as an inclusion eligibility criterion in 3 clinical trials, of which 2 are open and 1 is closed. Of the trials that contain NRAS Codon 59 Missense as an inclusion criterion, 1 is phase 1 (0 open) and 2 are phase 2 (2 open).
Trials with NRAS Codon 59 Missense in the inclusion eligibility criteria most commonly target colorectal carcinoma and colorectal adenocarcinoma .
Irinotecan, adavosertib, bevacizumab, binimetinib, and fluorouracil are the most frequent therapies in trials with NRAS Codon 59 Missense as an inclusion criteria .
Significance of NRAS Codon 59 Missense in Diseases
Colorectal Carcinoma +
NRAS is altered in 4.7% of colorectal carcinoma patients with NRAS Codon 59 Missense present in 0.01% of all colorectal carcinoma patients .
NRAS Codon 59 Missense is an inclusion criterion in 2 clinical trials for colorectal carcinoma, of which 1 is open and 1 is closed. Of the trials that contain NRAS Codon 59 Missense and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) .
Colorectal Adenocarcinoma +
NRAS is altered in 4.72% of colorectal adenocarcinoma patients with NRAS Codon 59 Missense present in 0.01% of all colorectal adenocarcinoma patients .
NRAS Codon 59 Missense is an inclusion criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS Codon 59 Missense and colorectal adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) .
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.